CHECKPOINT-INACT

NOVEL MECHANISMS INACTIVATING CHECKPOINT RESPONSE

Coordinatore	AGENCIA ESTATAL CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS    more  Organization address address: CALLE SERRANO 117 city: MADRID postcode: 28006 contact info Titolo: Mr. Nome: Eusebio Cognome: Jimenez Arroyo Email: send email Telefono: +34 91 5668852 Fax: +34 91 5668913
Nazionalità Coordinatore	Spain [ES]
Totale costo	100˙000 €
EC contributo	100˙000 €
Programma	FP7-PEOPLE Specific programme "People" implementing the Seventh Framework Programme of the European Community for research, technological development and demonstration activities (2007 to 2013)
Code Call	FP7-PEOPLE-2011-CIG
Funding Scheme	MC-CIG
Anno di inizio	2011
Periodo (anno-mese-giorno)	2011-11-01   -   2015-10-31

 Partecipanti

#	participant	country	role	EC contrib. [€]
1	AGENCIA ESTATAL CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS  Organization address address: CALLE SERRANO 117 city: MADRID postcode: 28006 contact info Titolo: Mr. Nome: Eusebio Cognome: Jimenez Arroyo Email: send email Telefono: +34 91 5668852 Fax: +34 91 5668913	ES (MADRID)	coordinator	100˙000.00

Mappa

 Word cloud

Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.

 Obiettivo del progetto (Objective)

'Eukaryotic cells need to preserve the integrity of their genomes. Conditions resulting in increased genome instability, defined as the generation and amplification of mutations and chromosomal aberrations, are associated with cancer predisposition and human pathologies. The DNA damage checkpoint acts as a surveillance mechanism that safeguards genome integrity in response to genotoxic insults. While the processes leading to DNA damage checkpoint activation have been extensively studied, little is known about mechanisms mediating its inactivation, which is essential to restore normal cell physiology and overcome genotoxic insults.

A genome-wide genetic screen performed by the research group identified novel Checkpoint Inactivating Factors (CIFs). These have been implicated in inactivation via proteolysis and subcellular sorting of several substrates but were previously not been implicated in the checkpoint response. Noteworthy, human orthologs of these factors have been involved in malignant transformation and cancer development.

In this project genetic, genomic, molecular biology and proteomic approaches will be used to characterize the role of these novel CIFs in the cellular response to genotoxic insults. The project also aims at identifying and characterizing CFI’s targets within the checkpoint pathway. The research proposed will contribute to elucidate how eukaryotic cells revert checkpoint activation to maintain genome integrity, thus providing a framework for the development of new therapeutic agents.

CIG funding will be invested in human resource in order to boost the project’s efficacy.'